SCHEMBL792161

SCHEMBL792161

CC(=O)Cn1cc(C)c2ccc(C)nc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
LMNA P02545 2/20 0.49
ABCC4 O15439 1/20 0.49
PKM P14618 1/20 0.49
PTGS1 P23219 1/20 0.49
CYP1A2 P05177 2/20 0.47
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NFKB1 P19838 1/20 0.47
BLM P54132 1/20 0.47
TP53 P04637 4/20 0.46
MAPT P10636 3/20 0.46
RXFP1 Q9HBX9 7/20 0.46
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
THRB P10828 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792163 0.81 LMNA (0.33) MEN1KMT2ALMNAABCC4PKM
SCHEMBL792371 0.80 MEN1 (0.57) MEN1KMT2ALMNAABCC4PKM
SCHEMBL791867 0.73 PTGDR2 (0.41) MEN1KMT2ALMNAABCC4PKM
SCHEMBL25899951 0.72 KMT2A (0.68) MEN1KMT2ALMNAABCC4PKM
SCHEMBL13809504 0.71 MEN1 (0.68) MEN1KMT2ALMNAABCC4PKM
SCHEMBL8530610 0.70 KMT2A (0.69) MEN1KMT2ALMNACYP1A2KDM4E
SCHEMBL15031283 0.70 KMT2A (0.37) MEN1KMT2ALMNAABCC4PKM
SCHEMBL12248454 0.69 KMT2A (0.80) MEN1KMT2ALMNAABCC4PKM
SCHEMBL16234633 0.68 MEN1 (0.47) MEN1KMT2ALMNAHSD17B10KDM4E
SCHEMBL16471645 0.66 CNR2 (0.48) MEN1KMT2ALMNAABCC4PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 MEN1 4753/4885KMT2A 1865/4885LMNA 4323/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 MEN1 4753/4885KMT2A 1865/4885LMNA 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.